Phage displayed cell binding peptides
AssigneeMdrna, Inc.
InventorsRichard E. Herman, Ekaterina G. Makienko, Douglas L. Badders, Mark Fuller
Life of this patent
Estimating the term…
Loading patent…
AssigneeMdrna, Inc.
InventorsRichard E. Herman, Ekaterina G. Makienko, Douglas L. Badders, Mark Fuller
Estimating the term…
This disclosure provides the construction, expression, and selection of the mutated genes that encode novel Trp cage polypeptides with desirable binding properties, as well as the novel Trp cage polypeptides themselves. The substances or targets bound by these novel Trp cage polypeptides may be but need not be proteins or polypeptides. Targets may include other biological or synthetic macromolecules as well as other organic and inorganic substances. Further, targets may also include a single or multiple cell or tissue types. The present invention achieves genetic variants of Trp cage-encoding nucleic acids through controlled random mutagenesis of the nucleic acids yielding a mixture of Trp cage polypeptides that are capable of binding targets.
A method for delivering a drug, compound or biologically active agent to a liver tissue of a subject, the method comprising:
A method for delivering a biologically active agent to a liver cell, the method comprising:
A method for preparing an RNAi agent for targeting to a liver tissue, the method comprising:
Dependencies are inferred from the claim text.